A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for unresectable locally advanced pancreatic adenocarcinoma.
Pancreatic Cancer
DRUG: Gemcitabine|DRUG: Nab-Paclitaxel
Number of patients with Adverse Events, 1 years
Response Rate, 1 years|Overall Survival time, 2 years
Gemcitabine plus nab-Paclitaxel is one of the standard chemotherapy for metastatic pancreatic adenocarcinoma. Gemcitabine plus nab-Paclitaxel realize the favorable anti-tumor effect and tolerable toxicity. Gemcitabine plus nab-Paclitaxel is a promising regimen for concurrent chemoradiotherapy, but the investigators need to know the safety in the case of the concurrent chemoradiotherapy.